ChronoScale Holdings Earnings Call Transcripts
Fiscal Year 2025
-
Q2 2025 revenue dropped sharply due to delayed enterprise sales, but personal health product revenue grew over 50% year-over-year. Management expects deferred sales to close in 2025 and anticipates personal health to contribute 25% of revenue this year.
-
Q1 2025 revenue declined year-over-year due to enterprise health softness, but gross margin improved to 54% and net loss narrowed. Personal health segment growth accelerated, supported by new distribution partnerships and a stronger Medicare pipeline.
Fiscal Year 2024
-
Record Q4 revenue and improved margins were driven by operational efficiencies and cost savings. Strategic partnerships and CMS reimbursement for Indego Personal set the stage for growth in 2025, with a strong backlog and expanding market access.
-
Q3 2024 saw $4.1M in sales and improved margins, with strong international growth offsetting U.S. procurement delays. Initial CMS reimbursement for Ekso Indego Personal marked a milestone, and a $5M public offering strengthened cash reserves.
-
Record Q2 sales and gross margin gains were driven by strong EksoHealth and international growth, while CMS reimbursement for Ekso Indego Personal marks a major milestone. The company expects significant revenue impact from Indego Personal in 2025 as the pipeline expands.